During the pandemic, consider all patients with cough and fever or suggestive symptoms to have COVID-19 until proven otherwise. See our topic Coronavirus disease 2019 (COVID-19).
The National Institute for Health and Care Excellence (NICE) in the UK has issued new guidelines on assessment and management of suspected or confirmed CAP during the COVID-19 pandemic.1,2 It has temporarily withdrawn its pre-COVID-19 guideline on diagnosis and management of pneumonia in adults.3
The key changes are that the new guidance:1,2
- Notes that the CRB-65 tool, recommended for severity assessment in its pre-COVID-19 guidance, is not validated in people with COVID-19, as it requires a blood pressure measurement, which may be ‘difficult or undesirable’ to obtain during the COVID-19 pandemic.1 It recommends using clinical judgement to assess severity and inform decisions on hospital admission during the pandemic.1
Signs and symptoms of severe illness are:1
- Severe shortness of breath at rest or difficulty breathing
- Coughing up blood
- Blue lips or face
- Feeling cold and clammy with pale or mottled skin
- Collapse or fainting (syncope)
- New confusion
- Becoming difficult to rouse
- Little or no urine output.
- Recommends considering a SARS-CoV2 polymerase chain reaction test in all patients with suspected moderate to severe CAP and in all patients who develop pneumonia while in hospital.2
- Recommends oral doxycycline first line (in preference to oral amoxicillin) in all non-pregnant patients with suspected bacterial CAP treated in the community with oral amoxicillin as an alternative.1 It includes oral doxycycline as a recommended first-line option in patients with moderate or severe bacterial CAP treated in hospital who can tolerate oral medicines and whose condition is not severe enough to need intravenous antibiotics.2
- Doxycycline has a broader spectrum of cover than amoxicillin, particularly against Mycoplasma pneumoniae and Staphylococcus aureus, which are more likely to be secondary bacterial causes of pneumonia during the COVID-19 pandemic.1
- National Institute for Health and Care Excellence. COVID-19 rapid guideline: managing suspected or confirmed pneumonia in adults in the community. April 2020 [internet publication].
- National Institute for Health and Care Excellence. COVID-19 rapid guideline: antibiotics for pneumonia in adults in hospital. May 2020 [internet publication].
- National Institute for Health and Care Excellence. Pneumonia in adults: diagnosis and management. Sep 2019 [internet publication]. WITHDRAWN during COVID-19 pandemic.
Globally, lower respiratory tract infections are the most deadly infectious disease, resulting in 3 million deaths worldwide in 2016. CAP is a serious health problem with high morbidity and mortality in all age groups worldwide, and is a major burden on healthcare resources.
A literature review found that the overall annual incidence of CAP in Europe is between 1.07 and 1.2 per 1000 person-years and 1.54 and 1.7 per 1000 people. The incidence of CAP increases with age to 14 per 1000 person-years in adults aged ≥65 years, and the incidence of CAP appears to be significantly higher in men than in women. It is the fifth leading cause of mortality in Europe. Estimates of mortality among patients range from 1% to 5% in outpatients, from 5.7% to 14% in general wards, and from 34% to 50% in the intensive care unit (especially in ventilated patients). Another study reported that mortality rates of CAP in Europe vary widely from country to country, ranging between <1% and 48%. The mortality rate for pneumococcal pneumonia is about 5%, rising to between 6% and 30% in adults with associated bacteraemia.
In the US, the annual incidence of CAP has been estimated at 24.8 cases per 10,000 adults. Pneumonia and influenza, when considered together, were the eighth leading cause of death (13.5 deaths per 100,000 population) and the leading infectious cause in the US in 2016.
Incidence increases significantly with age. Very advanced age has been associated with higher mortality from CAP.
Approximately 10% to 18% of all patients hospitalised for pneumonia are nursing home residents. Mortality in these patients may reach 55%. Patients in residential homes who develop pneumonia have traditionally been considered to have healthcare-associated pneumonia (HCAP) and not CAP. However, this definition has been criticised because it is not able to distinguish patients at risk for resistant pathogens, and each patient ought to be evaluated individually.
Colonisation with pathogenic bacteria is frequent in smokers and presents an increased risk of lung infections, especially pneumococcal pneumonia. One study of bacterial pneumonia found that HIV-infected smokers had >80% higher risk of developing pneumonia than those who had never smoked. Another study showed that current smokers with pneumococcal CAP often develop severe sepsis and require hospitalisation at a younger age despite having fewer comorbid conditions than older patients. Passive smoking at home is a risk factor for CAP in people aged 65 years or older.
There is clear evidence that alcohol consumption increases the risk for CAP. A meta-analysis of 14 studies found that people who consumed alcohol at all or in higher amounts had an 83% higher risk of CAP compared to people who consumed no alcohol or lower amounts (relative risk of 1.83). Consumption of 24 g, 60 g, and 120 g of pure alcohol daily has been shown to result in a relative risk for incident CAP of 1.12 (95% CI, 1.02-1.23), 1.33 (95% CI, 1.06-1.67), and 1.76 (95% CI, 1.13-2.77), respectively, relative to non-drinkers.
Oral and respiratory bacteria in dental plaques are shed into the saliva and can then be aspirated into the lower respiratory tract to cause infection. Aspiration pneumonia is one of the most serious problems in older patients. Low-quality evidence suggests that professional oral health care measures (e.g., brushing, swabbing, denture cleaning, mouth rinses) may reduce mortality due to pneumonia in nursing home residents compared to usual care.
CAP is one of the most common adverse effects associated with use of proton-pump inhibitors. This is thought to be due to a decrease in gastric acid secretion, which allows pathogens to colonise the upper respiratory tract more easily. Outpatient use of these drugs is associated with a 1.5-fold increased risk of CAP. H2 antagonists may also be associated with an increased risk of CAP.
Associated with a moderate increase in the risk of CAP. The main reasons are the increased risk of aspiration, hyperglycaemia, decreased immunity and impaired lung function, and coexisting morbidity.
One study found that diabetes (type 1 and type 2) was a risk factor for pneumonia-linked hospitalisation. Another study reported that pre-existing diabetes was associated with a higher risk of death after hospitalisation for CAP compared with patients hospitalised for non-infectious illnesses. The risk of severe pneumococcal bacteraemia is also higher in diabetic patients.
It is known that bacterial infections occur in 32% to 34% of hospitalised patients with cirrhosis, and approximately 15% of these infections are pneumonia (the third most common cause of infection in these patients). One study reported that chronic liver disease is a risk factor for pulmonary complications in patients hospitalised with pneumococcal pneumonia.
A case-control study found that prescribed opioids, especially those with immunosuppressive properties or higher doses, are associated with an increased risk of CAP in people with and without HIV infection.
Use of this content is subject to our disclaimer